Create a free Cannabis Equipment News account to continue

Endocanna Gets Patent for Cannabinoid DNA Test

The test helps consumers potentially avoid cannabis products that may cause negative health effects.

I Stock 1367538455

Endocanna Health announced the issuance of a U.S. patent for its DNA test that brings to healthcare hyper-personalized cannabinoid therapies based on user genetics. The test helps consumers potentially avoid cannabis products that may cause negative health effects such as cannabis-induced psychosis and rapid heart rate.

Emergency room visits resulting from cannabis consumption have skyrocketed where the plant is legal. In California, cannabis-related emergency care visits among those aged 65 and older rose 1,804% from 2005 to 2019. Such visits increased threefold in Colorado between 2012 and 2016 and increased fivefold in Ontario from 2003 to 2017. Endocanna's patented technology prevents cannabis-related emergency room visits by providing a consumer with a personalized view of how cannabinoids interact with their genetics and steering them to formulations more likely to provide a better health outcome.

Using an individual's genetics, Endocanna recommends precise cannabinoid ratios and terpene combinations as well as products that match those profiles. The DNA report each user receives is supported by peer-reviewed studies showing the association between each gene and condition. The company is also involved in multiple international clinical trials with top research institutions to study the genetic markers for various conditions.

This is the first patent awarded to Endocanna, and the first federal patent granted to a DNA technology for cannabis, which is still considered a Schedule I substance. The company has two other patents pending for its proprietary cannabinoid formulations and its Artificial Intelligence process that offers even more precise therapeutic recommendations. Endocanna's formulations are sold in the U.S. and through its partners in Brazil, England, and other countries worldwide.

"We're proud to provide a personalized platform that effectively addresses serious health concerns while removing the associated risk of adverse reactions," said Len May, Chief Executive Officer of Endocanna. "We know that everyone responds to cannabis products differently. That's why personalized cannabinoid therapeutics are essential to ensuring better health outcomes. We are thrilled to receive the intellectual property protection for our comprehensive DNA test that is pioneering endocannabinoid compatibility."

More in News